anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Large-scale genome-wide association studies (GWASs) have associated intronic variants in PDE4B, encoding cAMP-specific phosphodiesterase-4B (PDE4B), with increased risk for post-traumatic stress disorder (PTSD), as well as schizophrenia and substance use disorders that are often comorbid with it. However, the pathophysiological mechanisms of genetic risk involving PDE4B are poorly understood. To examine the effects of PDE4B variation on phenotypes with translational relevance to psychiatric disorders, we focused on PDE4B missense variant M220T, which is present in the human genome as rare coding variant rs775201287. When expressed in HEK-293 cells, PDE4B1-M220T exhibited an attenuated response to a forskolin-elicited increase in the intracellular cAMP concentration. In behavioral tests, homozygous Pde4b M220T male mice with a C57BL/6JJcl background exhibited increased reactivity to novel environments, startle hyperreactivity, prepulse inhibition deficits, altered cued fear conditioning, and enhanced spatial memory, accompanied by an increase in cAMP signaling pathway-regulated expression of BDNF in the hippocampus. In response to a traumatic event (10 tone-shock pairings), neuronal activity was decreased in the cortex but enhanced in the amygdala and hippocampus of Pde4b M220T mice. At 24 h post-trauma, Pde4b M220T mice exhibited increased startle hyperreactivity and decreased plasma corticosterone levels, similar to phenotypes exhibited by PTSD patients. Trauma-exposed Pde4b M220T mice also exhibited a slower decay in freezing at 15 and 30 d post-trauma, demonstrating enhanced persistence of traumatic memories, similar to that exhibited by PTSD patients. These findings provide substantive mouse model evidence linking PDE4B variation to PTSD-relevant phenotypes and thus highlight how genetic variation of PDE4B may contribute to PTSD risk.
The present invention relates to a chimeric receptor comprising an exodomain comprising a chemokine receptor ligand or a functional variant thereof, a transmembrane domain and an endodomain comprising an intracellular signalling domain. The receptor ligand is a C-C chemokine, a CXC chemokine, an XC chemokine or a functional variant thereof. Preferably the chimeric receptor specifically binds CCR9 and exodomain comprises CCL25 or Peptide 1, or the receptor binds XCR1 and the exodomain comprises XCL1 or XCL2. The chimeric receptor comprises a hinge domain between the chemokine and the transmembrane domain, a CD8α signal sequence and co-stimulatory signalling domains. Also disclosed are nucleic acid molecules encoding the chimeric receptor, a vector comprising the nucleic acid molecules, an immune cell comprising the nucleic acid molecules. The cell is preferably an NK cell, a dendritic cell, a NKT cell, a MSDC, a neutrophil, a macrophage, or a T-cell. Further disclosed is a method of producing the cell comprising introducing the nucleic acid molecules or vector into the cell, a pharmaceutical composition comprising the cell and their use in preventing, reducing risk of, or treating an autoimmune or inflammatory disease.
Patients receive pan-VEGFR/TIE2 (Vascular Endothelial Growth Factor Receptor/angopoeitin receptor2) tyrosine kinase inhibitor CEP-11981 PO QD for 5 days (Monday-Friday). Treatment repeats for up to 8 weeks in the absence of disease progression or unacceptable toxicity. If treatment is successful after 8 weeks, patients may receive up to 6 months of pan-VEGFR/TIE2 tyrosine kinase inhibitor CEP-11981.
Since a few years back, self-tonometry has been available in glaucoma care. Self-tonometry allows patients to measure their eye pressure themselves using a portable tonometer. Sankt Erik's Eye Hospital was the first healthcare provider in Sweden to use this new technology. The investigators have previously conducted studies that have shown good agreement between the measurements made by patients and the gold standard method, e.g. Goldman applanation tonometry (GAT) (Chen, Querat et al. 2016, Querat and Chen 2017). About one hundred patients perform pressure curves with self-tonometry annually.

As the method is used regularly, the investigators want to evaluate the impact of self-tonometry results on the clinician's choice of glaucoma treatment. The investigators also want to evaluate how often pressure peaks occur outside the clinic's opening hours and how much they differ from GAT.
The present invention relates to a use of kinases for treating and preventing fungal meningoencephalitis by pathogenic fungi of the genus  Cryptococcus.  Specifically, the present invention relates to a method for screening an antifungal agent characterized by measuring the amount or activity of a pathogenic-regulatory kinase protein of  Cryptococcus neoformans,  or the expression level of a gene encoding the protein; and an antifungal pharmaceutical composition comprising an inhibitor against a pathogenic-regulatory kinase protein of  Cryptococcus neoformans  or a gene encoding the same. An antifungal agent for treating meningoencephalitis, etc. can be effectively screened by using the method for screening an antifungal agent according to the present invention, and meningoencephalitis, etc. can be effectively treated by using the antifungal pharmaceutical composition according to the present invention. Thus, the present invention can be widely used in related industrial fields such as pharmaceutical and biotechnology fields.
NEW MATERIAL:A thrombin-bonding substance having the following properties. Molecular weight, 185,000, 92,000, 46,500 and 31,000 in reduced state and 200,000, 48,000 and 40,000 in unreduced state; affinity, having strong affinity to thrombin; activity, capable of activating protein C by bonding with active thrombin and prolonging the coagulation time of blood; stability, stable to denaturation agent (sodium dodecylsulfate or urea). USE:A fibrinolysis-promoting agent and anticoagulant. PREPARATION:Fresh human urine is added with benzamidine hydrochloride and aprotinin and subjected to ion-exchange chromatography. The adsorbed fraction is eluted with tris-HCl buffer solution, concentrated and passed through a column packed with thrombin bonded to a carrier. The adsorbed active fraction is eluted with a tris-HCl buffer solution and subjected to concentration and gel-filtration to obtain the objective thrombin-bonding substance.
<P>PROBLEM TO BE SOLVED: To provide a repeater device which transfers data collected from an implantable medical device to a repository for data, for an advanced patient management system.  <P>SOLUTION: The repeater device maintains the data collected from the medical device in a memory in the repeater device temporarily. After that, the repeater device transfers the data to the repository, while performing the following adjustments. In one embodiment, the data is transferred based on a state of communication medium between the repeater device and the repository. The repeater device transfers the data through a communications medium to the repository, when the state of the communication medium is most appropriate for data transmission, by detecting the state of the communication medium. In another embodiment, the data is transferred based on the degree of urgency of the data collected from the medical device. By analyzing the collected data, the repeater device decides whether the patient exactly enters a state of urgency, or whether the patient has already entered the state of urgency, and determines the degree of urgency. The repeater device then determines when to transfer the data to the repository based on the degree of urgency.  <P>COPYRIGHT: (C)2010,JPO&INPIT
While the acute phase of coronavirus disease 2019 (COVID-19) is associated with worsening cardiac outcomes, it is unclear whether it affects the outcome of patients with ST-segment elevation myocardial infarction (STEMI) after the acute phase. In addition, while many studies compared the course of STEMI during the COVID-19 pandemic with the years before the outbreak, we evaluated the course of STEMI during the pandemic according to whether or not patients had history of COVID-19. Patients diagnosed with STEMI during the ongoing COVID-19 pandemic were included in the study. The Ministry of Health database was analyzed retrospectively, and patients with (n = 191) and without (n = 127) a history of polymerase chain reaction (PCR) confirmed COVID-19 infection were divided into groups. Clinical and angiographic characteristics were assessed. The rates of in-hospital major adverse cardiac events (MACE) were higher in those who had a history of PCR-verified COVID-19 infection. Angiographic and procedural findings indicating successful reperfusion were better in patients without a history of COVID-19. A history of COVID-19 infection (odds ratio 1.40, 95% confidence interval 1.25-1.60, P < .01) independently predicted MACE. A history of COVID-19 infection is a predictor of worse outcomes following coronary intervention and in-hospital MACE among patients with STEMI.
Patients receive 3 doses of tetanus as in Arm I. Patients receive high-dose melphalan IV on day -2 and undergo AHSCT on day 0.
Previous investigations on the impact of oral zinc sulfate treatment on newborns' serum bilirubin levels have produced conflicting results. As a result, the goal of this clinical study was to evaluate how oral zinc sulfate affected the levels of serum bilirubin in term infants who were admitted to the neonatal intensive care unit. The study was conducted at the Neonatal Care Unit of Besat Hospital in Sanandaj, Kurdistan Province, as a double-blind randomized controlled trial. The participants included term infants (37-42 weeks of gestation) who required phototherapy and were admitted to the neonatal intensive care unit. A total of 290 infants were enrolled and randomly divided into two groups. The intervention group received oral zinc sulfate supplementation at a dosage of 1 mg/kg per day in addition to phototherapy, while the placebo group received an equivalent amount of placebo daily. Bilirubin measurements were obtained at the initiation of the intervention and subsequently every 24 h until discharge. The collected data were analyzed using STATA software version 17. After the infants were randomly allocated to the zinc-sulfate and placebo groups, the study outcomes, including the average changes in bilirubin levels after intervention, the hours of phototherapy, and the number of days of hospitalization, were analyzed and compared for a total of 160 infants in the zinc sulfate group and 130 infants in the placebo group. The reduction in bilirubin levels in infants receiving zinc sulfate was (- 3.75 ± 0.19 CI 95% - 4.12, - 3.37) and for placebo group was (- 1.81 ± 0.15 CI 95% - 2.12, - 1.50) 24 h after the intervention. Furthermore, 48 and 72 h following the intervention, bilirubin levels in the intervention group demonstrated a more substantial decline. The zinc sulfate group had a shorter hospital stay (2.13 ± 0.04 vs. 2.83 ± 1.42) and required less phototherapy hours than the placebo group (6.21 ± 2.16 vs. 8.78 ± 1.40).           Conclusions: Oral zinc sulfate supplementation in term neonates with hyperbilirubinemia decreased the level of bilirubin levels, duration of phototherapy, and hospital stay.           Trial registration: IRCT, IRCT20220806055625N1. Study Registered 25 December 2022, http://irct.ir/trial/66,722 .
Multiple system atrophy-cerebellar type (MSA-C) exhibits faster disease progression than does hereditary spinocerebellar degeneration (hSCD). In this study, we aimed to investigate the differences in the treatment effects and sustainability of intensive rehabilitation between patients with hSCD and those with MSA-C. Forty-nine patients (hSCD = 30, MSA-C = 19) underwent a 2- or 4-week intensive rehabilitation program. Balance function was evaluated using the scale for the assessment and rating of ataxia (SARA) and the balance evaluation systems test (BESTest) at pre-intervention, post-intervention, and 6-month follow-up. Notably, both groups demonstrated beneficial effects from the rehabilitation intervention. However, differences were observed in the magnitude and duration of these effects. In the hSCD group, the SARA scores at follow-up remained similar to those at baseline, indicating sustained benefits. However, the MSA-C group showed some deterioration in SARA scores compared with baseline scores but maintained improvements on the BESTest, demonstrating partial sustainability. Differences, mainly in sustainability, were observed between the hSCD and MSA-C groups. This may be due to varying rates of symptom progression. The findings of this study are significant when considering the frequency of follow-ups based on disease type.
This study involves the collection of medical information to create a computer database (registry) for patients with PH. The information will be entered into the registry by your physician, healthcare provider or a staff member of the Mayo Clinic Hyperoxaluria Center. The computer web site for the registry is secure and protected by a required password. Some information which will be entered may include your age at first symptoms of PH,kidney stone history, lab values, kidney function, and your health over time. Information for a patient can only be viewed by the appropriate physician and staff. Once the information is entered into the registry, you will only be identified by a code number.
A cosmetic composition comprising an extract of Prunus serrulata var. spontanea bark is provided to inhibit melanogenesis and show excellent anti-oxidative capacity, thereby being used for whitening and protecting skin. The whitening cosmetic composition comprises 0.01-5.0 wt.% of an extract of Prunus serrulata var. spontanea bark. The extract is prepared by using at least one solvent selected from the group consisting of distilled water, ethanol, butylene glycol, glycerin, and propylene glycol. The cosmetic composition is in the form of skin, nutritive lotion, nutritive cream, massage cream or a nutritive essence.
Insufficient angiogenic stimulation and dysregulated glycolipid metabolism in senescent vascular endothelial cells (VECs) constitute crucial features of vascular aging. Concomitantly, the generation of excess senescence-associated secretory phenotype (SASP) and active immune-inflammatory responses propagates within injured vessels, tissues, and organs. Until now, targeted therapies that efficiently rectify phenotypic abnormalities in senescent VECs have still been lacking. Here, we constructed a Pd/hCeO2-BMS309403@platelet membrane (PCBP) nanoheterostructured capsule system loaded with fatty acid-binding protein 4 (FABP4) inhibitors and modified with platelet membranes and investigated its therapeutic role in aged mice. PCBP showed significant maintenance in aged organs and demonstrated excellent biocompatibility. Through cyclic tail vein administration, PCBP extended the lifespan and steadily ameliorated abnormal phenotypes in aged mice, including SASP production, immune and inflammatory status, and age-related metabolic disorders. In senescent ECs, PCBP mediated the activation of vascular endothelial growth factor (VEGF) signaling and glycolysis and inhibition of FABP4 by inducing the synthesis of hypoxia-inducible factor-1α, thereby reawakening neovascularization and restoring glycolipid metabolic homeostasis. In conclusion, the PCBP nanocapsule system provides a promising avenue for interventions against aging-induced dysfunction.
Adipose tissue (AT) expands in response to excessive energy intake by hyperplasia or hypertrophy. While hyperplasia is associated with preservation of insulin sensitivity, hypertrophic AT exerts a number of metabolic defects. The mechanisms by which hyperplasia is suppressed at the expense of AT hypertrophy remain unknown, but it is expected that the hypertrophy of adipocytes is primarily driven by insufficient recruitment and differentiation of available preadipocytes. The limitation of hyperplasia occurs already in non-obese healthy subjects who are genetically predisposed to Type 2 Diabetes. Using these and control subjects, the LIMEX project aims to analyze the mechanisms of AT expandability. The project will combine in vivo characterization of AT and in vitro studies on human preadipocytes derived from AT biopsies obtained during clinical study. In vitro, proliferation, adipogenesis and lipogenesis of adipose cells will be monitored and these properties will be related to the degree of AT hypertrophy in vivo, insulin sensitivity and genetic predisposition to metabolic complications.
Mucosal markings are placed clearly outside the visible margin of the lesion (polyp) by placing superficial cautery marks with the tip of the endoscopic snare approximately 3 mm away from the polyp margin. Successful marking with diathermy is established by visual identification of white circular "dots" around the entire outer border of the lesion. EMR is then performed as per standard technique as described above.
The present invention discloses the creation of a compound solution, oxytocic, coagulant with immediate synergic action and for topical use, for intrauterine application, postpartum, cesarean section, curettage or systemic hormonal alterations in other medical specialties, performing surgeries or medical treatments in human or animal organs and tissues that present pathological hemorrhages due to diseases, trauma, or post-surgery. Said solution includes two vials of injectable Ergometrine of up to two millimeters, two injectable Oxytocin in 0.4 mg, and 10 IU of two vials of Etamsylate contained in a 20 ml syringe filled with 12 ml of hydrogen peroxide at a concentration of four to six percent. Said formula allows applying it directly on the tissue with pathological bleeding in the specific case of uterine bleeding, intrauterine, and directly on the endometrial tissue, acting effectively and immediately. Also, it applies topically and specifically on the pathological hemorrhagic tissue and other organs or tissues to avoid its absorption and passage into the bloodstream and the secondary or adverse effects caused either at regular doses or at very high concentrations, used parenterally with the aim of curing and saving women suffering from pathological uterine bleeding or other bleeding conditions. Herein, when applied systemically, it never reaches high concentrations directly to the hemorrhagic tissue. Also, its efficiency, speed, and direct disposition ensure effective results, inhibiting pathological bleeding by causing a sustained, effective, and sufficiently robust uterine contraction, favoring and causing coagulation within the blood vessels of the endometrial tissue or others presenting bleeding. Said components are already available on the market and in medical practice, found separately and for systemic applications, allowing intrauterine application of human and veterinary use and effectively in other branches of medicine.
The present invention relates to a pharmaceutical combination comprising an inhibitor of the enzyme 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG CoA) reductase (statin), which is simvastatin, fluvastatin,a torvastatin or cerivastatin and a fibric acid derivative (fibrate), which is fenofibrate, ciprofibrate or bezafibrate, and to a method of administering these medicaments for the treatment of dyslipidemia (especially mixed hyperlipidemia and familial combined hyperlipidemia) in diabetics and non-diabetics.According to the method claimed herein, separate dosage forms of statin-fibrate combinations properly ordered in a common blister card or a dispenser releasing one-tablet-per-day could be an effective approach for the treatment at different days of dyslipidemia, providing for patient's compliance, efficacy in normalising lipid parameters, safety in terms of myopathy and lower cost, as compared to conventional every day treatment.Selection of the statin and the fibrate for combination should depend both on pharmacokinetic (or the formulation characteristics of each drug) and pharmacodynamic properties of drugs. Regarding pharmacokinetic properties, each drug of the combination should eliminate during the day of treatment. In this order, interactions of each other should be avoided. Relating to pharmacodynamic properties, most suitable statin for the combination is one that effectively lowers LDL-cholesterol but also lowers triglycerides. Respectively, most suitable fibrate for the combination is one that effectively lowers triglycerides and raises HDL-cholesterol but also lowers LDL-cholesterol to a certain degree. A combination comprising a statin and a fibrate with pharmacodynamic properties complementry to each other should provide for efficacy at different days of treatment comparable to the efficacy of conventional everyday treatment with the same combination.
Breast cancer is the most common malignant tumor in women, which accounts for 6.9% of all cancer-related deaths. Early diagnosis is crucial for making the best clinical decision and improving the prognosis of patients. Circulating tumor cells (CTCs) have been regarded as significant tumor biomarkers. Herein, we designed a colorimetric biosensor for breast cancer CTCs quantification based on ladder-branch hybridization chain reaction (HCR) and DNA flowers/gold nanoclusters (DFs/AuNCs) nanozyme. With the assistance of complementary DNA labeled on magnetic beads (MBs), the cleavage products of RNA-cleaving DNAzymes (RCDs) could be rapidly captured, subsequently triggering ladder-branch HCR. In addition, the DFs/AuNCs nanozyme was applied for colorimetric analysis, which further improved the sensitivity for the detection of target CTCs. Benefiting from specific RCDs, ladder-branch HCR and DFs/AuNCs, we achieved a superior detection limit of 3 cells/mL as well as a broad linear range of 10 cells/mL to 104 cells/mL. Conclusively, this colorimetric biosensor achieved sensitively and selectively detection of breast cancer CTCs without the participation of enzymes at room temperature, which might provide new insight into the early detection of breast cancer.
The invention discloses a stable perindopril indapamide tablet and a preparation technology. The pharmaceutical composition is composed of the following components: perindopril tert-butylamine, indapamide, lactose, hydroxypropyl cellulose, sodium carboxymethyl starch, silicon dioxide, and magnesium stearate. Powder is directly pressed to prepare the pharmaceutical composition. The properties, dissolution rate, water content, content, crystal form, and dissolving-out behavior in different medium with different pH values of the prepared perindopril indapamide tablet are similar with those of commercial products. Furthermore, the dissolution curve shows that the difference of tablets in a batch and the difference of tablets in different batches is prominently less than that of commercial products. Compared with the commercial products, the stability of the provided tablet is better in production and storage. The clinical effectiveness and safety are guaranteed. Moreover, the preparation technology is simple, and the production cost is reduced.
High frequency pulsed repetitive magnetic stimulation at 100 % resting motor threshold will be delivered using a figure of 8 air film cooled coil attached to the Magstim® Rapid 2 machine. Resting motor threshold will be determined minimum energy needed to elicit the a reliable visible contraction in the contra-lateral first interosseous muscle using single pulse rTMS applied to the area between C1-C3 using the 10-20 international EEG electrode system. For stimulation, the coil will be positioned on the scalp corresponding to F4 then F3 electrode position using the 10-20 international EEG system. Real stimulation will consist of delivering 1200 pulses at 20 hz frequency to F4 location followed by the same stimulation to F3. The total time needed to deliver pulses is 20 minutes.